279 related articles for article (PubMed ID: 19250190)
1. Steroid hormone transforming aldo-keto reductases and cancer.
Penning TM; Byrns MC
Ann N Y Acad Sci; 2009 Feb; 1155():33-42. PubMed ID: 19250190
[TBL] [Abstract][Full Text] [Related]
2. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
Penning TM; Burczynski ME; Jez JM; Hung CF; Lin HK; Ma H; Moore M; Palackal N; Ratnam K
Biochem J; 2000 Oct; 351(Pt 1):67-77. PubMed ID: 10998348
[TBL] [Abstract][Full Text] [Related]
3. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
[TBL] [Abstract][Full Text] [Related]
5. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
Byrns MC; Penning TM
Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
7. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
Byrns MC; Jin Y; Penning TM
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
[TBL] [Abstract][Full Text] [Related]
9. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells.
Rizner TL; Lin HK; Peehl DM; Steckelbroeck S; Bauman DR; Penning TM
Endocrinology; 2003 Jul; 144(7):2922-32. PubMed ID: 12810547
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
Byrns MC; Mindnich R; Duan L; Penning TM
J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
[TBL] [Abstract][Full Text] [Related]
11. Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells.
Rizner TL; Lin HK; Penning TM
Chem Biol Interact; 2003 Feb; 143-144():401-9. PubMed ID: 12604227
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
14. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.
Steckelbroeck S; Jin Y; Oyesanmi B; Kloosterboer HJ; Penning TM
Mol Pharmacol; 2004 Dec; 66(6):1702-11. PubMed ID: 15383625
[TBL] [Abstract][Full Text] [Related]
15. Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: Substrate and reaction specificity in the reduction of 11-keto-C
Endo S; Morikawa Y; Kudo Y; Suenami K; Matsunaga T; Ikari A; Hara A
J Steroid Biochem Mol Biol; 2020 May; 199():105586. PubMed ID: 31926269
[TBL] [Abstract][Full Text] [Related]
16. Pre-receptor regulation of the androgen receptor.
Penning TM; Jin Y; Rizner TL; Bauman DR
Mol Cell Endocrinol; 2008 Jan; 281(1-2):1-8. PubMed ID: 18060684
[TBL] [Abstract][Full Text] [Related]
17. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men.
Blouin K; Richard C; Brochu G; Hould FS; Lebel S; Marceau S; Biron S; Luu-The V; Tchernof A
J Endocrinol; 2006 Dec; 191(3):637-49. PubMed ID: 17170221
[TBL] [Abstract][Full Text] [Related]
18. Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis.
Hevir N; Vouk K; Sinkovec J; Ribič-Pucelj M; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):217-26. PubMed ID: 21232532
[TBL] [Abstract][Full Text] [Related]
19. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action.
Steckelbroeck S; Jin Y; Gopishetty S; Oyesanmi B; Penning TM
J Biol Chem; 2004 Mar; 279(11):10784-95. PubMed ID: 14672942
[TBL] [Abstract][Full Text] [Related]
20. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
